An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin
This is an open-label dose escalation trial using ABI-007 plus carboplatin.
Non-Small Cell Lung Cancer (NSCLC)
DRUG: ABI-007 (Abraxane) and Carboplatin
Safety Outcomes: incidence of treatment emergent adverse events., Treatment duration|Efficacy Outcomes: percentage of patients who achieve an objective confirmed complete or partial overall antitumor response, Treatment duration
This is a multicenter study conducted at study sites in Russia and the Ukraine where various doses of ABI-007 (Abraxane) will be given in combination with carboplatin to patients with non-small cell lung cancer to determine the recommended dose and schedule for this combination therapy for Phase III trials. The primary objective of this study is to obtain preliminary information on the antitumor activity and adverse events of ABI-007 in combination with carboplatin.